Aprepitant for Nausea and Vomiting

This trial aims to determine if the medication aprepitant can reduce nausea and vomiting after ear surgery. Participants will receive either aprepitant or a placebo (a pill with no active medicine) before their surgery to assess which is more effective. This trial is ideal for adults scheduled for specific ear surgeries, such as tympanoplasty or stapedectomy. Those relying on hormonal birth control should note that aprepitant might reduce its effectiveness, so additional contraception is recommended for a month after surgery. As a Phase 4 trial, this research seeks to understand how the already FDA-approved and effective treatment benefits more patients.

If you are taking medications that affect certain liver enzymes (CYP3A4 or CYP2CP), you may need to stop them because they could interact with the study medication. It's best to discuss your current medications with the study team to see if any changes are needed.

Research has shown that aprepitant is generally safe for use. Studies have demonstrated its effectiveness in reducing nausea and vomiting, particularly in cancer patients undergoing chemotherapy. For example, one study found that aprepitant controlled vomiting in 83.33% of patients, compared to only 45.83% of those who did not take the drug. This suggests that aprepitant is both effective and well-tolerated.

Regarding safety, another study examined how adult patients with chemotherapy-related nausea responded to aprepitant. The study confirmed that patients tolerated it well, with no major side effects reported.

Aprepitant is unique because it targets the neurokinin-1 (NK1) receptor, which plays a key role in the body's nausea and vomiting pathway. Unlike standard treatments like ondansetron or metoclopramide, which primarily target serotonin receptors, aprepitant offers a different mechanism of action. This makes it particularly exciting for researchers, as it could provide relief for patients who do not respond well to existing medications, potentially offering a new option for managing nausea and vomiting.

Research has shown that aprepitant helps reduce nausea and vomiting. In this trial, participants in the treatment arm will receive 80 mg of aprepitant. Previous studies have demonstrated that this dosage significantly reduces vomiting after surgery more than it reduces nausea. Another study found it very effective in preventing nausea and vomiting caused by chemotherapy. Aprepitant also reduces the need for additional anti-nausea medications and improves overall treatment success. This medication has proven effective and is already used to prevent these symptoms in other situations.²⁶⁷⁸⁹